These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23436256)

  • 21. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].
    Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M
    Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges of assessment and treatment of ultra high risk for psychosis in an adolescent.
    Boričević Maršanić V; Jukić J; Flander M
    Psychiatr Danub; 2018 Jun; 30(Suppl 4):166-168. PubMed ID: 29864753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth.
    Preti A; Raballo A; Meneghelli A; Cocchi A; Meliante M; Barbera S; Malvini L; Monzani E; Percudani M
    Early Interv Psychiatry; 2022 Apr; 16(4):342-351. PubMed ID: 33951751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive predictors of transition to psychosis: medium- to long-term findings from a sample at ultra-high risk for psychosis.
    Lin A; Yung AR; Nelson B; Brewer WJ; Riley R; Simmons M; Pantelis C; Wood SJ
    Psychol Med; 2013 Nov; 43(11):2349-60. PubMed ID: 23388122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
    Bushe CJ; Bradley AJ; Doshi S; Karagianis J
    Int J Clin Pract; 2009 Dec; 63(12):1743-61. PubMed ID: 19840151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early psychosis detection program in Chile: A first step for the South American challenge in psychosis research.
    Gaspar PA; Castillo RI; Maturana A; Villar MJ; Ulloa K; González G; Ibaceta O; Ortiz A; Corral S; Mayol R; De Angel V; Aburto MB; Martínez A; Corcoran CM; Silva H
    Early Interv Psychiatry; 2019 Apr; 13(2):328-334. PubMed ID: 30548415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo.
    McHugh MJ; McGorry PD; Yuen HP; Hickie IB; Thompson A; de Haan L; Mossaheb N; Smesny S; Lin A; Markulev C; Schloegelhofer M; Wood SJ; Nieman D; Hartmann JA; Nordentoft M; Schäfer M; Amminger GP; Yung A; Nelson B
    Schizophr Res; 2018 May; 195():543-548. PubMed ID: 29055567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness.
    Preti A; Cella M
    Schizophr Res; 2010 Oct; 123(1):30-6. PubMed ID: 20727717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy and clinical characteristics of ultra-high-risk for psychosis according to conversion status: a naturalistic observational study.
    Kim E; Jang JH; Park HY; Shim G; Hwang JY; Kim SN; Kwon JS
    Early Interv Psychiatry; 2012 Feb; 6(1):30-7. PubMed ID: 22029630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
    Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
    J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.
    Nelson B; Yuen HP; Wood SJ; Lin A; Spiliotacopoulos D; Bruxner A; Broussard C; Simmons M; Foley DL; Brewer WJ; Francey SM; Amminger GP; Thompson A; McGorry PD; Yung AR
    JAMA Psychiatry; 2013 Aug; 70(8):793-802. PubMed ID: 23739772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.
    Kindermann SS; Dolder CR; Bailey A; Katz IR; Jeste DV
    Drugs Aging; 2002; 19(4):257-76. PubMed ID: 12038878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.